Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elaina Coleborn

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2025
Cancer-derived extracellular vesicles in natural killer cell immune evasion: Molecular mechanisms and therapeutic insightsElaina Coleborn, Raluca Ghebosu, Joy Wolfram, et al.
Toxicon : Official Journal of the International Society on Toxinology|July 23, 2025
Antitumor activity of violacein in osteosarcoma, neuroblastoma and triple-negative breast cancer spheroidsBeatriz Aires-Lopes, Elaina Coleborn, Fernando Souza-Fonseca-Guimarães, et al.
Trends in Immunology|May 20, 2026
Beyond the bench: teaching grant writing in immunotherapy trainingGraham Leggatt, Janin Chandra, Zhian Chen, et al.
Journal of Extracellular Vesicles|September 30, 2025
Lipoprotein Association Fluorometry (LAF) as a Semi-Quantitative Characterization Tool to Assess Extracellular Vesicle-Lipoprotein BindingRaluca Ghebosu, Jenifer Pendiuk Goncalves, Nur Indah Fitri, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growthAndrew N Wilkinson, Rui Chen, Elaina Coleborn, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Molecular Therapy Oncolytics|October 2, 2023
miR-146a inhibits ovarian tumor growth <i>in vivo</i> via targeting immunosuppressive neutrophils and enhancing CD8<sup>+</sup> T cell infiltrationRui Chen, Elaina Coleborn, Chintan Bhavsar, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 10, 2025
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapyLouisa Alim, Siddharth Adityan, Rui Chen, et al.
Clinical and Translational Medicine|January 7, 2025
Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CARPui Yeng Lam, Natacha Omer, Josh K M Wong, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2025
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapyJoshua K M Wong, Pui Yeng Lam, Elaina Coleborn, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2025
Cancer-derived extracellular vesicles in natural killer cell immune evasion: Molecular mechanisms and therapeutic insightsElaina Coleborn, Raluca Ghebosu, Joy Wolfram, et al.
Toxicon : Official Journal of the International Society on Toxinology|July 23, 2025
Antitumor activity of violacein in osteosarcoma, neuroblastoma and triple-negative breast cancer spheroidsBeatriz Aires-Lopes, Elaina Coleborn, Fernando Souza-Fonseca-Guimarães, et al.
Trends in Immunology|May 20, 2026
Beyond the bench: teaching grant writing in immunotherapy trainingGraham Leggatt, Janin Chandra, Zhian Chen, et al.
Journal of Extracellular Vesicles|September 30, 2025
Lipoprotein Association Fluorometry (LAF) as a Semi-Quantitative Characterization Tool to Assess Extracellular Vesicle-Lipoprotein BindingRaluca Ghebosu, Jenifer Pendiuk Goncalves, Nur Indah Fitri, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growthAndrew N Wilkinson, Rui Chen, Elaina Coleborn, et al.
Nature Communications|November 14, 2024
Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationTimothy R McCulloch, Gustavo R Rossi, Louisa Alim, et al.
Molecular Therapy Oncolytics|October 2, 2023
miR-146a inhibits ovarian tumor growth <i>in vivo</i> via targeting immunosuppressive neutrophils and enhancing CD8<sup>+</sup> T cell infiltrationRui Chen, Elaina Coleborn, Chintan Bhavsar, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 10, 2025
Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapyLouisa Alim, Siddharth Adityan, Rui Chen, et al.
Clinical and Translational Medicine|January 7, 2025
Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CARPui Yeng Lam, Natacha Omer, Josh K M Wong, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2025
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapyJoshua K M Wong, Pui Yeng Lam, Elaina Coleborn, et al.
Pageof 1